Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
The Future of Dermatologic Laser and Energy-Based Device Technology
Description
The speaker discusses the future of dermatologic laser and energy-based device technology, emphasizing that AI integration, smarter devices, and more personalized treatments are likely to shape the field. He notes that the technology side of dermatology remains underfunded and argues for stronger industry support. Near-term developments are expected to include more reproducible tightening and lifting devices, expanded home-use devices, broader use of combination treatments, and increased application of lasers for medical conditions beyond aesthetics. He raises concerns about complications from unskilled or unsupervised providers and the possibility of stricter scope-of-practice rules. The talk then highlights focal point laser technology, a non-ablative device that delivers deeper, adjustable energy with less pain than some fractional lasers, and describes its use for skin tightening, eyelid and jawline lifting, neck rejuvenation, scar improvement, and hand rejuvenation. The speaker also describes promising combination approaches, especially focal point laser with pulsed dye laser for resistant port-wine stains and combining devices for acne scars, which can improve outcomes without increasing side effects. A major theme is laser-assisted drug delivery, which he calls underutilized but central to the future; he describes using post-laser channels to enhance delivery of agents such as tranexamic acid, rapamycin, cisplatin, and 5-FU for conditions like melasma, post-inflammatory hyperpigmentation, tuberous sclerosis-related lesions, and hypertrophic actinic keratoses. Finally, he notes renewed interest in ablative resurfacing—both fractional and fully ablative—despite ongoing concerns about healing time and complications when used improperly, concluding that older laser modalities still have major clinical value.
View moreConclusions
- The presentation concludes that laser and energy-based dermatologic treatments will become faster, more personalized, and more widely used over the next five years, especially as AI is integrated into device design and treatment planning.
- It argues that focal point laser technology may offer meaningful clinical improvements in tightening, lifting, scar treatment, and rejuvenation with less pain and downtime than older approaches.
- The speaker suggests that combining technologies, such as focal point laser with pulsed dye laser or RF microneedling with fractional lasers, can produce better outcomes than using either treatment alone.
- The research and clinical experience presented indicate that laser-assisted drug delivery is highly promising and should become routine because non-ablative and ablative treatments can create useful skin channels for topical medication uptake.
- The data presented support that laser-assisted delivery of agents such as tranexamic acid, poly-L-lactic acid, rapamycin, cisplatin, and 5-FU can improve outcomes in conditions like melasma, scars, and vascular or inflammatory lesions.
- The presentation concludes that focal point and related laser devices can be used safely across many skin types and body areas, including the face, neck, hands, scars, and even darker skin tones, when used appropriately.
- It suggests that some effects, such as brow or eyelid lifting and jawline tightening, are real but temporary and may require maintenance treatments.
- The speaker emphasizes that complication risk is rising when laser technologies are used by unskilled or unsupervised providers, implying the need for greater training and possibly stricter scope-of-practice controls.
- The presentation concludes that ablative resurfacing is experiencing a resurgence because it still has substantial value for wrinkles, laxity, scars, and other difficult problems despite requiring more downtime.
- Overall, the research presented portrays laser-based dermatology as entering a new phase in which smarter devices, combination protocols, and drug-delivery applications expand its role beyond traditional cosmetic use into broader medical treatment.
- Hashemi DA, Tao J, Wang JV, Geronemus RG. Dermatol Surg. 2025 Jan 29;51(6):647-648. Combination Radiofrequency Microneedling and 1550-nm Nonablative Fractional Resurfacing for Acne Scarring.#10.1097/dss.0000000000004555
- Wang JV, Friedman PM, Agron S, Konda A, Parker C, Geronemus RG. Derm Surg 2022;48(8):822-6.
- Evaluation of Device-Based Cutaneous Channels Using Optical Coherence Tomography: Impact for Topical Drug Delivery. Wang JV, Mehrabi JN, Zachary CB, Geronemus RG. Dermatol Surg. 2022 Jan 1;48(1):120-125.#10.1097/dss.0000000000003275
- Rkein A, Ozog D, Waibel JS. Treatment of Atrophic Scars with Fractionated CO2 Laser Facilitating Delivery of Topically Applied Poly-L-Lactic Acid. Dermatol Surg 2014;40:624-631.#10.1016/j.jaad.2014.01.833
- Ibrahim O, Ionta S, Depina J, Petrell K, Arndt KA, Dover JS. Safety of laser-assisted delivery of topical poly-L-lactic acid in the treatment of upper lip rhytides: a prospective, rater-blinded study. Dermatol Surg 2019;00:1-7.#10.1097/dss.0000000000001743
- Wang JV, Ugonabo N, Geronemus RG. Fractional ablative laser-assisted delivery of topical poly-L-lactic acid: a 2.5-year safety review. Dermatol Surg 2022 Feb 1;48(2):258-259.#10.1097/dss.0000000000003333